Humacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Humacyte (NASDAQ:HUMA) announced its earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01, Zacks reports. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 12,727.47%. The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.46 million.

Here are the key takeaways from Humacyte’s conference call:

• Symvess sales increased to $0.5 million in Q1 2026 from $0.1 million a year ago, but management said adoption is still too slow and that stronger commercial execution is needed.
• The company reshaped its commercial organization with new senior hires, including a Chief Commercial Officer and Chief Surgical Officer, to improve surgeon education, hospital penetration, and IDN coverage.
• Humacyte said its dialysis access Phase III trial is on track for top-line interim results around June 11, with 120 patients enrolled and a supplemental BLA planned for the second half of 2026 if results are positive.
• The company restructured its workforce in May, cutting 45 employees, and expects about $0.8 million in severance charges despite projecting roughly $14.3 million in savings for the rest of 2026.
• Humacyte ended Q1 with $48.9 million in cash and restricted cash; however, it reported a $17.6 million net loss, driven largely by lower non-cash income from contingent earn-out remeasurement.

Humacyte Trading Down 9.8%

Shares of HUMA traded down $0.10 during trading hours on Friday, hitting $0.90. The company had a trading volume of 4,092,227 shares, compared to its average volume of 6,513,796. The firm has a market cap of $200.26 million, a P/E ratio of -1.58 and a beta of 2.31. The stock’s 50 day moving average price is $0.85 and its 200 day moving average price is $1.06. The company has a quick ratio of 2.95, a current ratio of 3.69 and a debt-to-equity ratio of 20.08. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.93.

Institutional Trading of Humacyte

A number of institutional investors have recently modified their holdings of HUMA. Atom Investors LP purchased a new stake in shares of Humacyte during the fourth quarter worth about $25,000. Financial Advisors Network Inc. purchased a new stake in shares of Humacyte during the second quarter worth about $28,000. Prudential Financial Inc. purchased a new stake in shares of Humacyte during the second quarter worth about $28,000. Equitable Holdings Inc. purchased a new stake in shares of Humacyte during the third quarter worth about $29,000. Finally, Imprint Wealth LLC purchased a new stake in shares of Humacyte during the third quarter worth about $33,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HUMA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. Wall Street Zen downgraded Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, April 11th. BTIG Research decreased their price objective on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday. Benchmark decreased their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Humacyte currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.